SF-12v2 在糖尿病患者中的可靠性和有效性评估。
Assessment of Reliability and Validity of SF-12v2 among a Diabetic Population.
机构信息
Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA.
Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, AR, USA; Division of Health Services Research, Psychiatric Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
出版信息
Value Health. 2018 Apr;21(4):432-440. doi: 10.1016/j.jval.2017.09.007. Epub 2017 Nov 10.
OBJECTIVES
To validate the Medical Outcomes Study Short Form version 2 (SF-12v2) in diabetic patients.
METHODS
Adults with self-reported diabetes from the Medical Expenditure Panel Survey (2011-2013) were identified. Reliability (internal consistency and test-retest) and validity (construct, concurrent, criterion, and predictive) of the SF-12v2 were assessed. The SF-12v2 consists of two normalized composite scores: the physical component summary score (PCS12) and the mental component summary score (MCS12). Confirmatory factor analysis was conducted to assess the instrument structure. Concurrent (convergent and discriminant) validity was assessed by a multitrait-multimethod matrix using the Patient Health Questionnaire, the Kessler Scale, and perceived health and mental health questions. The predictive validity was assessed by estimating future limitations. The concurrent validity was tested by comparing the MCS12, PCS12, and utility scores (six-dimensional health state short form) across comorbidity scores.
RESULTS
The final sample comprised 2214 diabetic patients with mean normalized (population mean 50; range 0-100) PCS12 and MCS12 scores of 40.81 (standard error 0.33) and 49.82 (standard error 0.26), respectively. The PCS12 and MCS12 scores showed good internal consistency (Cronbach α: PCS12 0.85; MCS12 0.83) and acceptable test-retest reliability (intraclass correlation coefficient: PCS12 0.72; MCS12 0.63) and produced acceptable goodness-of-fit indices (normed fit index 0.95; comparative fit index 0.95; root mean square error of approximation 0.11 [95% confidence interval 0.1017-0.1188]). The PCS12 and MCS12 were moderately correlated with perceived health and perceived mental health. The MCS12 was highly correlated with the Patient Health Questionnaire and the Kessler Scale. Both the PCS12 and the MCS12 could predict the future health limitations. The PCS12, MCS12, and utility scores demonstrated sensitivity to the presence of comorbidity scores.
CONCLUSIONS
The SF-12v2 is a valid generic instrument for measuring quality of life in diabetic patients.
目的
验证医学结局研究简表第二版（SF-12v2）在糖尿病患者中的适用性。
方法
从医疗支出调查（2011-2013 年）中确定自我报告患有糖尿病的成年人。评估 SF-12v2 的信度（内部一致性和重测信度）和效度（结构、同时性、标准和预测）。SF-12v2 由两个标准化综合评分组成：生理成分综合评分（PCS12）和心理成分综合评分（MCS12）。采用多维多方法矩阵，利用患者健康问卷、凯斯勒量表以及感知健康和心理健康问题，对工具结构进行验证性因子分析。通过估计未来的限制，评估预测效度。通过比较合并症评分下的 MCS12、PCS12 和效用评分（六维健康状态简表）来评估同时性（收敛性和辨别性）效度。
结果
最终样本包括 2214 名糖尿病患者，其标准化（人口平均值 50；范围 0-100）PCS12 和 MCS12 评分分别为 40.81（标准误差 0.33）和 49.82（标准误差 0.26）。PCS12 和 MCS12 评分显示出良好的内部一致性（Cronbach α：PCS12 0.85；MCS12 0.83）和可接受的重测信度（组内相关系数：PCS12 0.72；MCS12 0.63），并产生了可接受的拟合优度指数（标准化拟合指数 0.95；比较拟合指数 0.95；均方根误差逼近 0.11[95%置信区间 0.1017-0.1188]）。PCS12 和 MCS12 与感知健康和感知心理健康呈中度相关。MCS12 与患者健康问卷和凯斯勒量表高度相关。PCS12 和 MCS12 均能预测未来的健康限制。PCS12、MCS12 和效用评分对合并症评分的存在具有敏感性。
结论
SF-12v2 是一种用于测量糖尿病患者生活质量的有效通用工具。
Zotero 插件